Aktis Oncology, Inc. AKTS
16.51 USD -0.54 (-3.14%)
Nov 12, 2026, 12:51 PM EST
16.40 Day range 16.99
13.96 52-week range 34.19
- YTD
- -26.32%
- 1 year
- -26.32%
News
benzinga.com Aktis Oncology Q3 EPS $(0.54) Misses $(0.48) Estimate, Sales $3.905M Miss $4.016M Estimate Aktis Oncology (NASDAQ:AKTS) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.48) by 12.5 percent. This is a 97.18 percent increase over losses of…
zacks.com Does Aktis (AKTS) Have the Potential to Rally 105.62% as Wall Street Analysts Expect? The mean of analysts' price targets for Aktis (AKTS) points to a 105.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts…
benzinga.com Wedbush Reiterates Outperform on Aktis Oncology, Maintains $35 Price Target Wedbush analyst David Nierengarten reiterates Aktis Oncology (NASDAQ:AKTS) with a Outperform and maintains $35 price target.- benzinga.com Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519 Phase 1b BActinium-2 clinical trial is evaluating AKY-2519 in patients with non-small cell lung cancer (NSCLC) and other B7-H3 expressing tumorsEnrollment is ongoing in the Phase 1b BActinium-1…
- benzinga.com Oppenheimer Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $40 Oppenheimer analyst Jeff Jones initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Outperform rating and announces Price Target of $40.
benzinga.com Wedbush Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $35 Wedbush analyst David Nierengarten initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Outperform rating and announces Price Target of $35.
benzinga.com BMO Capital Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $37 BMO Capital analyst David Lebowitz initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Outperform rating and announces Price Target of $37.
benzinga.com Micron and 15 Other Stocks To Play The AI Buildout Race: They Are Still 20% Below Highs Bank of America screened its AI baskets for Buy-rated stocks down over 20% from highs. Micron carries the widest gap to target.
benzinga.com Aktis Oncology Q2 EPS $(0.44) Misses $(0.43) Estimate, Sales $3.384M Beat $2.000M Estimate Aktis Oncology (NASDAQ:AKTS) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.43) by 2.33 percent. This is a 98.03 percent increase over losses of…- benzinga.com JP Morgan Maintains Overweight on Aktis Oncology, Raises Price Target to $33 JP Morgan analyst Jessica Fye maintains Aktis Oncology (NASDAQ:AKTS) with a Overweight and raises the price target from $30 to $33.
benzinga.com DigitalOcean, Agios Pharmaceuticals, Kingsoft Cloud And Other Big Stocks Moving Higher On Tuesday US stocks were mixed, Nasdaq fell 1%. DigitalOcean shares rose after strong revenue growth and earnings guidance. Other big gainers include CRNX, MAAS, and AGIO.
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Vicore Pharma Holding (NASDAQ:VCRE) stock rose 149.8% to $42.47 during Monday's after-market session. Crinetics Pharmaceuticals (NASDAQ:CRNX) stock moved upwards by 99.85% to $84.0. The…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Innovative Eyewear (NASDAQ:LUCY) stock moved upwards by 95.4% to $1.49 during Monday's regular session. The market value of their outstanding shares is at $4.8 million. Seer (NASDAQ:SEER)…
benzinga.com This Aktis Oncology Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday Top Wall Street analysts changed outlook on top names. For all changes, including upgrades/downgrades, visit analyst ratings page. Consider buying AKTS stock? Analysts weigh in.- benzinga.com Raymond James Initiates Coverage On Aktis Oncology with Strong Buy Rating, Announces Price Target of $40 Raymond James analyst Christopher Raymond initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Strong Buy rating and announces Price Target of $40.
benzinga.com Rezolve AI, Bakkt, Seagate And Other Big Stocks Moving Higher On Friday U.S. stocks were mixed, with the Dow Jones gaining 100 points. Rezolve AI (RZLV) jumped 11.9%, and other stocks such as ALOY and FWRD also rose.- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com HC Wainwright & Co. Maintains Buy on Aktis Oncology, Raises Price Target to $35 HC Wainwright & Co. analyst Robert Burns maintains Aktis Oncology (NASDAQ:AKTS) with a Buy and raises the price target from $33 to $35.
- benzinga.com Aktis Oncology's AKY-2519 Shows Robust Tumor Uptake And Favorable Dosimetry Across Solid Tumors In First-In-Human B7-H3 Radiopharmaceutical Data Presented At ASCO 2026 Data to be presented across two posters at the 2026 American Society of Clinical Oncology (ASCO) Annual MeetingCombined results evaluating AKY-2519 across several B7-H3 expressing tumor types,…
- benzinga.com Aktis Oncology Q1 EPS $(0.38) Beats $(0.44) Estimate, Sales $3.227M Beat $1.750M Estimate Aktis Oncology (NASDAQ:AKTS) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.44) by 13.64 percent. This is a 97.96 percent increase over losses of…
benzinga.com Aktis Oncology Starts Phase 1b Clinical Study Of AKY-25191 In Participants With Metastatic Castration-resistant Prostate Cancer Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations,…
benzinga.com This Hyperfine Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Wednesday Top analysts change outlook on Hyperfine Inc, Legence, and Aktis Oncology with Buy/Outperform ratings and price targets. See other analysts' views.- benzinga.com William Blair Initiates Coverage On Aktis Oncology with Outperform Rating William Blair analyst Alexandra Ramsey initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Outperform rating.
- benzinga.com TAktis Oncology To Present First Clinical Imaging And Dosimetry Data For AKY-2519 At the 2026 American Society of Clinical Oncology Annual Meeting Aktis Oncology, Inc. (NASDAQ:AKTS) (the "Company"), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including…
- benzinga.com HC Wainwright & Co. Maintains Buy on Aktis Oncology, Raises Price Target to $33 HC Wainwright & Co. analyst Robert Burns maintains Aktis Oncology (NASDAQ:AKTS) with a Buy and raises the price target from $30 to $33.
benzinga.com This Aktis Oncology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Top analysts change outlook on top names. See all analyst rating changes on Benzinga's analyst ratings page. Consider AKTS stock based on analyst views.- benzinga.com HC Wainwright & Co. Initiates Coverage On Aktis Oncology with Buy Rating, Announces Price Target of $30 HC Wainwright & Co. analyst Robert Burns initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Buy rating and announces Price Target of $30.
benzinga.com Aktis Oncology's AKY-1189 Receives FDA Fast Track Designation U.S. FDA Fast Track designation granted to AKY-11891 for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have progressed on or after prior systemic…
benzinga.com This GCI Liberty Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Tuesday - benzinga.com Crude Oil Down 1%; Webuy Global Shares Spike Higher
- benzinga.com Why Uxin Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
benzinga.com 12 Information Technology Stocks Moving In Thursday's Pre-Market Session - benzinga.com 12 Information Technology Stocks Moving In Friday's After-Market Session
benzinga.com 12 Information Technology Stocks Moving In Wednesday's Pre-Market Session - benzinga.com Why JD.com Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
- benzinga.com 12 Information Technology Stocks Moving In Tuesday's Intraday Session
- benzinga.com Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
- benzinga.com Nasdaq Surges Over 100 Points; Nvidia Posts Upbeat Q1 Results
- benzinga.com Why NVIDIA Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket
- benzinga.com Why XP Shares Are Trading Lower By Around 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
benzinga.com Why Urban Outfitters Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Information Technology Stocks Moving In Monday's After-Market Session
- benzinga.com Why Virios Therapeutics Shares Are Trading Lower By Around 48%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- benzinga.com US Stocks Mixed; Li Auto Shares Plummet After Q1 Results
- benzinga.com Gold Down Over 1%; AC Immune Shares Spike Higher
- benzinga.com Why Akoustis Technologies Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- benzinga.com 12 Information Technology Stocks Moving In Monday's Intraday Session
- benzinga.com Crude Oil Surges Over 1%; Amprius Technologies Shares Plunge
- benzinga.com 12 Information Technology Stocks Moving In Wednesday's After-Market Session
- benzinga.com Earnings Scheduled For February 13, 2024 Companies Reporting Before The Bell • LCI Indus (NYSE:LCII) is likely to report quarterly earnings at $0.18 per share on revenue of $838.27 million.